The EU Commission accepts the commitment offered by a pharmaceutical company for excessive pricing (Aspen)

In February 2021, the European Commission’s (“Commission”) long-running excessive pricing case against Aspen was brought to a close, with Aspen accepting a series of forward-looking pricing and supply commitments, but avoiding any fines or requirements to repay all of the higher prices charged (see VBB on Competition Law, Volume 2021, No. 2). This appears to have been a good result for Aspen, particularly in comparison with the € 5.2 million fine received in the 2016 decision from the Italian competition authority. Against this backdrop, it is

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • Van Bael & Bellis (Brussels)
  • Van Bael & Bellis (Brussels)

Quotation

Michael Clancy, Samuel Hall, The EU Commission accepts the commitment offered by a pharmaceutical company for excessive pricing (Aspen), 10 February 2021, e-Competitions June 2021, Art. N° 100835

Visites 152

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues